Extensive mucocutaneous, oesophageal and otic lichen planus secondary to nivolumab therapy.
Loading...
Embargo End Date
ICR Authors
Authors
Ferguson, L
Ho, B
Weir, J
Francis, N
West, K
Rathbone, B
Larkin, J
Heelan, K
Ho, B
Weir, J
Francis, N
West, K
Rathbone, B
Larkin, J
Heelan, K
Document Type
Journal Article
Date
2021-03-01
Date Accepted
2020-10-23
Abstract
We report a 73-year-old female with metastatic renal cell carcinoma who developed a widespread lichenoid reaction following nivolumab treatment. The timeline of the reaction strongly correlated with the nivolumab treatment and subsequent cessation. Our patient had cutaneous, mucosal, otic, ophthalmic and oesophageal involvement, demonstrating the potentially extensive nature of lichenoid reactions to anti-programmed cell death receptor-1 (anti-PD1) therapies. Although lichenoid reactions to anti-PD1 therapies are now well recognized, there have been no previous reports of otic or oesophageal involvement in the literature. Although cutaneous lichenoid reactions do not tend to be severe or treatment limiting, more widespread systemic lichenoid reactions are challenging to manage, particularly in the context of malignancy. This very unusual case highlights the importance of considering involvement beyond the skin in all lichenoid skin reactions.
Citation
Skin Health and Disease, 2021, 1 (1), pp. e8 -
DOI
Source Title
Skin Health and Disease
Publisher
Oxford University Press (OUP)
ISSN
2690-442X
eISSN
2690-442X
2690-442X
2690-442X